Estimated impact of ECHELON-1 overall survival on productivity costs in stage III/IV classical Hodgkin lymphoma in the United States

Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial

(2023) Tycel Phillips et al.   LEUKEMIA & LYMPHOMA

NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022

(2022) Richard T. Hoppe et al.   Journal of the National Comprehensive Cancer Network

The impact of classic Hodgkin lymphoma (cHL) on informal caregivers: Results from the cHL—Real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT) study.

(2022) Darcy R. Flora et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

(2022) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimation of the Number of Individuals Living With Metastatic Cancer in the United States

(2022) Lisa Gallicchio et al.   JNCI-Journal of the National Cancer Institute

Oncology Simulation Model: A Comprehensive and Innovative Approach to Estimate and Project Prevalence and Survival in Oncology

(2022) Brian Bloudek et al.   Clinical Epidemiology

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

(2021) Stefanie Kreissl et al.   Lancet Haematology

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial

(2021) Umberto Ricardi et al.   Blood Advances

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

(2020) Richard T. Hoppe et al.   Journal of the National Comprehensive Cancer Network

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

(2019) René-Olivier Casasnovas et al.   LANCET ONCOLOGY

Employment Status and Work Ability in Long-Term Young Adult Cancer Survivors

(2019) Alv A. Dahl et al.   Journal of Adolescent and Young Adult Oncology

Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma

(2019) Deborah M Stephens et al.   BLOOD

National and State Estimates of Lost Earnings From Cancer Deaths in the United States

(2019) Farhad Islami et al.   JAMA Oncology

Impact of Cancer on Employment

(2019) Victoria S. Blinder et al.   JOURNAL OF CLINICAL ONCOLOGY

Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial

(2018) Andrea Gallamini et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

(2018) Joseph M. Connors et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis

(2018) Steven M. Bair et al.   ONCOLOGIST

Employment status and health related quality of life among Hodgkin-lymphoma survivors’– results based on data from a major treatment center in Hungary

(2017) Ferenc Magyari et al.   Health and Quality of Life Outcomes

Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation

(2016) C. E. Kiserud et al.   ACTA ONCOLOGICA

Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalatedPlus Four Cycles of BEACOPPbaselinein Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial

(2016) Patrice Carde et al.   JOURNAL OF CLINICAL ONCOLOGY

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

(2016) Peter Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Working with cancer: health and employment among cancer survivors

(2015) Tainya C. Clarke et al.   ANNALS OF EPIDEMIOLOGY

Employment and income losses among cancer survivors: Estimates from a national longitudinal survey of American families

(2015) Anna Zajacova et al.   CANCER

Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time—a population-based comparative study

(2015) I. Glimelius et al.   Journal of Cancer Survivorship

How to Estimate Productivity Costs in Economic Evaluations

(2014) Marieke Krol et al.   PHARMACOECONOMICS

Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

(2012) Leo I. Gordon et al.   JOURNAL OF CLINICAL ONCOLOGY

Employment and insurance in survivors of Hodgkin lymphoma and their siblings: a questionnaire study

(2012) Aileen B. Chen et al.   LEUKEMIA & LYMPHOMA

Are lymphoma survivors really at higher risk for unemployment/underemployment?

(2012) Patrick Tang et al.   LEUKEMIA & LYMPHOMA

Productivity Costs of Cancer Mortality in the United States: 2000–2020

(2008) Cathy J. Bradley et al.   JNCI-Journal of the National Cancer Institute